Doctors abandoning Invokana over increased risk of amputations

September 27, 2017 - The latest reported adverse side effect connected to Invokana – an increased risk of amputation – has led some doctors to stop prescribing the diabetes drug. Read More

New, contradictory evidence from Xarelto makers could lead to retrial for plaintiff

September 21, 2017 - There is an effective lab test to protect patients taking Xarelto, but that isn’t what jurors heard during last month’s trial against Johnson & Johnson’s Janssen Pharmaceuticals and... Read More

Taxotere MDL trial dates set

September 20, 2017 - Taxotere, a chemotherapy drug approved by the Food and Drug Administration (FDA) to treat breast cancer and other forms of cancer, has been linked to permanent hair loss. Read More

New trial for testosterone litigation starts next week

September 13, 2017 - Plaintiffs maintain that despite not being designed to treat symptoms of age-related testosterone decline, manufacturers marketed the products as “fountain of youth” drugs to lure men... Read More

More than 800 Physiomesh incidents filed with FDA report pain, suffering

September 6, 2017 - Since Physiomesh was first approved by the FDA in 2010, medical professionals have reported 839 adverse events, including injuries and at least nine deaths, naming the mesh device as the... Read More

Concern over Invokana adverse side effects continues to grow

August 25, 2017 - Reports of amputations connected to canagliflozin, the key ingredient in brand name medications Invokana and Invokamet, continue to underscore the drug’s dangers. Read More

New warning labels were evidence in $417 million talc-ovarian cancer win

August 23, 2017 - Other talcum powder products now warn women about the danger of genital use. Johnson & Johnson has declined to provide similar warnings on its Johnson’s Baby Powder, which contains talc... Read More

Los Angeles jury links talc to ovarian cancer, awarding woman $417 million

August 21, 2017 - A Los Angeles jury awarded plaintiff Eva Echeverria $417 million, finding Johnson & Johnson talcum powder products responsible for her ovarian cancer. Read More

Retrievable IVC filter use down, but still high considering risks

August 16, 2017 - The use of retrievable inferior vena cava, or IVC, filters has fallen since the FDA issued a safety warning in 2010 about fracture and other adverse effects linked to the devices, but the... Read More

Third Xarelto Trial Begins This Week

August 9, 2017 - Last month, U.S. District Judge Eldon E. Fallon rejected the latest attempts by Xarelto makers to dodge consumers’ efforts to hold them accountable. Judge Fallon denied the defendants’... Read More

back to top